This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Armed with anywhere between $2 trillion and $4 trillion of “dry powder”—with about half of that targeted to healthcare—privateequity firms have a lot of capital to put to work. ENT and allergy is relatively new to privateequity investment, with approximately ten major platforms currently operating.
People have argued for years that equity deals “dominate” IB activity in India, but this is a bit of a stretch if you look at the fees by product type: Deals themselves are diversified across different sectors. Mumbai is the financialcapital, but some firms also operate in cities such as Bangalore, Kolkata (Calcutta), and Delhi NCR.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Financial Capital 
52 
Let's personalize your content